VZL 2007, 76(4):117-122

Risk of the Statin Therapy

Miroslav Brndiar1, Lucie Chadimová1, Ladislav Jebavý1, Jan M. Horáček ORCID...1, Martina Prixová2
1 Univerzita obrany, katedra válečného vnitřního lékařství Fakulty vojenského zdravotnictví, Hradec Králové
2 II. interní klinika Fakultní nemocnice a Lékařské fakulty UK v Hradci Králové

V retrospektivní studii byl sledován výskyt nežádoucích účinků terapie statiny. V celém souboru (n = 120) se nežádoucí účinky objevily u 18 nemocných, tj. v 15 % případů. Většina z nich byla jen mírná a nevyžadovala přerušení terapie. Nebyl prokázán významný rozdíl ve výskytu nežádoucích účinků mezi simvastatinem (n = 60) a lovastatinem (n = 60). Dále byla sledována účinnost obou typů statinů na lipidové spektrum. Ani v tomto případě nebyl prokázán významný rozdíl v účinnosti mezi těmito typy statinů na celkový cholesterol, HDL-cholesterol, LDL-cholesterol a triacylglyceroly. Vzhledem k prakticky stejné účinnosti obou typů statinů je ekonomicky výhodné zahajovat terapii hyperlipoproteinémie lovastatinem.

Keywords: Statiny; Hyperlipoproteinémie; Nežádoucí účinky

In the retrospective study an incidence of undesirable effects of the statin therapy was observed. In the whole group (n = 120) undesirable effects appeared in 18 ill people, i.e. in 15 % of the cases. Most of them were only slight and it was not necessary to interrupt the therapy. Significant difference in incidence of undesirable effects between simvastatin (n = 60) and lovastatin (n = 60) was not proved. Further the effectiveness of both types of statins on the lipid spectrum was observed. Not even in this case the significant difference in effectiveness among these types of statins on general cholesterol, HDL-cholesterol, LDL-cholesterol and triacylglycerols was proved. Considering almost the same effectiveness of both types of statins it is economically advantageous to begin the therapy of the hyper-lipoproteinemia with lovastatin.

Keywords: Statins; Hyperliproteinemia; Undesirable effects

Received: March 12, 2007; Published: December 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Brndiar, M., Chadimová, L., Jebavý, L., Horáček, J.M., & Prixová, M. (2007). Risk of the Statin Therapy. Vojenské Zdravotnické Listy, 76(4), 117-122
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. BAIGENT, C. - KEECH, A. - KEARNEY, PM., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90.056 participants in 14 randomized trials of statins. Lancet, 2005, vol. 366, p. 1267-1278. Go to original source... Go to PubMed...
    2. BALLANTYNE, CM. - KORSINI, A. - DAVIDSON, MH., et al. Risk for myopathy with statin therapy in high-risk patients. Arch. Intern. Med., 2003, vol. 10, p. 553-564. Go to original source... Go to PubMed...
    3. CANNON, CP. - BRAUNWALD, E. - McCABE, CH., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med., 2004, vol. 250, p. 1495-1504. Go to original source... Go to PubMed...
    4. DAUGIRD, AJ. - CROWELL, K. - SASSEN, J. Do statins cause myopathy? J. Fam. Pract., 2003, vol. 12, p. 973-975.
    5. ENDO, A. - KURODA, M. - TANZAWA, K. Competitive inhibition of 3-hydroxy-3-methyl-glutary coenzyme A reductase by ML-236 A and ML-236 B fungal metabolites, having hypocholesterolemic activity. FEBS Lett., 1976, vol. 72, p. 323-326. Go to original source... Go to PubMed...
    6. ILLINGWORTH, DR., et al. Comparative hypolipidemic effects of lovastatin and simvastatin in patients with heterozygous familial hypercholesterolemia. Atherosclerosis, 1992, vol. 96, p. 53-64. Go to original source... Go to PubMed...
    7. LAROSA, JC. - GRUNDY, SM. - WATERS, DD., et al. Intensive lipid lowering with atoravastatin patients with stable coronary disease. N. Engl. J. Med., 2005, vol. 352, p. 1425-1435. Go to original source... Go to PubMed...
    8. Lipid research clinics program. JAMA, 1984, vol. 252, p. 2545-2548.
    9. PEDERSEN, TR. - FAERGEMAN, O. - KASTELEIN, JJP., et al. High-dose atorvastatin versus usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA, 2005, vol. 294, p. 2437-2445. Go to original source... Go to PubMed...
    10. POYNTER, JN. - GRUBER, SB. - HIGGINS, PDR., at al. Statins and the risk of colorectal cancer. N. Engl. J. Med., 2005, vol. 352, p. 2184-2192. Go to original source... Go to PubMed...
    11. ROSENSON, RS. Current overview of statin-induced myopathy. Am. J. Med., 2004, vol. 116, p. 408-416. Go to original source... Go to PubMed...
    12. SEVER, PS. - DAHLOF, B. - POULTER, NR., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average of lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multiple randomized controlled trial. Lancet, 2003, vol. 361, p. 1149-1158. Go to original source... Go to PubMed...
    13. Scandinavian simvastatin survival study group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet, 1994, vol. 344, p. 1383-1389.
    14. SHEPHERD, J. - COBBE, SM. - FORD, I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med., 1995, vol. 333, p. 1301-1307. Go to original source... Go to PubMed...
    15. SHEPHERD, J. - HUNNINGHAKE, DB. - BARTER, P. Guidelines for lowering lipids to reduce coronary artery disease risk: A comparison of rosuvastatin with atorvastatin, pravastatin and simvastatin for achieving lipid-lowering goals. Am. J. Cardiol., 2003, vol. 91, p. 11C-19C. Go to original source... Go to PubMed...
    16. STAFFA, JA. - GREEN, L. Cerivastatin and reports of fatal rhabdomyolisis. N. Engl. J. Med., 2002, vol. 346, p. 539-540. Go to original source... Go to PubMed...
    17. STEINBERG, D. - GOTTO, AM. Jr. Preventing coronary artery disease by lowering cholesterol levels: fifty years from bench to bedside. JAMA, 1999, vol. 282, p. 2043-2050. Go to original source... Go to PubMed...
    18. The Multiple Risk Factor Intervention Trial (MRFIT): a national study of primary prevention of coronary heart disease. JAMA, 1976, vol. 235, p. 825-827. Go to original source...

    Return to the content